Cytokine inhibitors, particularly those specific for tumour necrosis factor and, more recently, the interleukin 23-T-helper-17 cell pathway, have been very successful in the treatment of disease manifestations in a variety of tissues, even though targeting the interleukin 23-T-helper-17 cell pathway may be more effective in treating psoriasis than arthritis [14]. In Western adults, it is prevalent at 2-4%, and psoriatic arthritis develops in 20-30% of psoriasis sufferers [15]. Here, IL37 is linked to psoriasis.